Acromegaly screening protocol established to define prevalence in associated somatic disorders
Background
Acromegaly is a rare endocrine disorder often associated with type 2 diabetes mellitus (T2DM) and other somatic conditions, where its prevalence may be underestimated. Current diagnostic challenges include potential discordance between growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, complicating disease activity interpretation. A standardized screening approach is needed to accurately identify affected individuals within high-risk populations, ensuring timely diagnosis and management. This protocol aims to fill that gap by defining a systematic screening program.
Study Design
This protocol outlines a screening program designed to identify acromegaly in patients with confirmed clinically significant associated somatic disorders. The primary objective is to determine the percentage of acromegaly cases within this screened population. Diagnostic methods include laboratory assessments of Insulin-like Growth Factor I (IGF-1) and Growth Hormone (GH) levels, along with an Oral Glucose-Tolerance Test (OGTT). Instrumental examination involves Magnetic Resonance Imaging (MRI) to confirm findings.
Why It Matters
This defined screening protocol offers a crucial framework for systematic identification of acromegaly in patients with pre-existing somatic disorders, particularly those with conditions like type 2 diabetes. By standardizing the use of IGF-1, GH, OGTT, and MRI, it aims to reduce diagnostic delays and improve patient outcomes. This approach could lead to earlier intervention for acromegaly, mitigating long-term complications associated with delayed diagnosis. Ultimately, this program provides a practical, evidence-based strategy for clinicians to proactively screen at-risk populations, moving towards more effective disease management.
acromegaly
screening
diagnosis
igf-1
gh
ogtt